Steven Sablotsky Resigns From Noven Board of Directors

Resignation Concludes Previously Announced Management Transition

-- Noven Pharmaceuticals, Inc. (Nasdaq:NOVN),announced that Steven Sablotsky has resigned from Noven's board of directors in order to pursue outside interests.

Commenting on his resignation, Mr. Sablotsky said: "This is the final step in a Noven management transition that we began in early 1998 with the hiring of Bob Strauss. We set out to build a management team with expertise in product development, manufacturing and commercialization. That team is in place, has had good success over the last several years, and is committed to taking Noven to new heights."

Robert C. Strauss, Noven's President, CEO and Chairman, said: "On behalf of the board of directors and everyone at Noven, I'd like to thank Steven for nearly 15 years of service and commitment to Noven. In that time, he helped establish the technology, the infrastructure and the talented employee base that permits Noven to develop, manufacture and commercialize the most innovative transdermal patches in the world. We wish him all the best in his future endeavors."

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery technologies and products. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot™, licensed to Novogyne, and Estradot™, licensed to Novartis) and combination estrogen/progestin transdermal delivery systems (including Combipatch™, licensed to Novogyne, and Estalis®, licensed to Novartis). With a range of additional products in development, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems. For additional information, visit the company's website at

Investor & Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.